Evolution Wealth Advisors LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Evolution Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 303 shares of the company’s stock, valued at approximately $236,000.

A number of other hedge funds also recently made changes to their positions in the company. Iyo Bank Ltd. acquired a new stake in Eli Lilly and Company during the 1st quarter valued at approximately $311,000. Sivia Capital Partners LLC boosted its stake in shares of Eli Lilly and Company by 5.0% during the 1st quarter. Sivia Capital Partners LLC now owns 1,868 shares of the company’s stock valued at $1,454,000 after buying an additional 89 shares during the last quarter. Monument Capital Management boosted its stake in shares of Eli Lilly and Company by 1.3% during the 1st quarter. Monument Capital Management now owns 2,916 shares of the company’s stock valued at $2,268,000 after buying an additional 38 shares during the last quarter. Azzad Asset Management Inc. ADV raised its holdings in Eli Lilly and Company by 2.5% in the first quarter. Azzad Asset Management Inc. ADV now owns 1,814 shares of the company’s stock valued at $1,411,000 after acquiring an additional 45 shares in the last quarter. Finally, Saxon Interests Inc. bought a new position in Eli Lilly and Company during the 1st quarter valued at $261,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.9 %

Shares of LLY stock opened at $898.10 on Thursday. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $918.50. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The business’s fifty day moving average is $821.29 and its 200-day moving average is $745.62. The stock has a market cap of $853.56 billion, a PE ratio of 132.27, a price-to-earnings-growth ratio of 1.98 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the previous year, the business earned $1.62 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. Equities analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Bank of America reissued a “buy” rating and issued a $1,000.00 target price on shares of Eli Lilly and Company in a research report on Monday, June 24th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. The Goldman Sachs Group boosted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. BMO Capital Markets restated an “outperform” rating and set a $1,001.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday. Finally, Citigroup lifted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $812.72.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $885.91, for a total value of $172,732,959.98. Following the completion of the transaction, the insider now directly owns 97,583,810 shares in the company, valued at $86,450,473,117.10. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, major shareholder Lilly Endowment Inc sold 194,978 shares of Eli Lilly and Company stock in a transaction on Monday, June 17th. The stock was sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the sale, the insider now owns 97,583,810 shares of the company’s stock, valued at $86,450,473,117.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 858,742 shares of company stock worth $735,573,781. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.